Advertisement

Topics

Eyenovia Inc. Company Profile

03:05 EDT 24th June 2018 | BioPortfolio

Eyenovia is a specialty biopharmaceutical company building a portfolio of next generation topical eye treatments based on its proprietary delivery and formulation platform for micro-therapeutics. Eyenovia’s pipeline is currently focused on the late-stage development of micro-therapeutics for glaucoma and other eye diseases. For more information, visit www.eyenoviabio.com.


News Articles [22 Associated News Articles listed on BioPortfolio]

Eye Drug Delivery Firm Eyenovia Sets IPO Range as Plans Come Into Focus

Eyenovia, a startup that has adapted an inkjet printing technique into a way to deliver drugs to the eye, is providing more clarity on an initial public offering intended to finance late-stage clinica...

Terms set by Eyenovia for IPO

An initial public offering of 2.73 million shares was priced by New York-based startup Eyenovia at $10 to $12 each.  -More- 

Eyenovia seeks to go public

Ophthalmic-focused Eyenovia Inc. filed for its initial public offering.

Eyenovia's myopia drug advances to late-stage study

Eyenovia will commence in 2019 a late-stage study of MicroPine, a microtherapeutic formulation of atropine, in patients with  -More- 

Eyenovia completes $27.3 million initial public offering

Eyenovia has closed its initial public offering of 2.73 million shares of its common stock, according to a press release.Gross proceeds from the offering, before underwriting discounts and commissions...

Eyenovia nets $25.4mm via initial public offering

Ophthalmic-focused Eyenovia Inc. netted $25.4mm through its initial public offering of 2.73mm common shares at $10 each.

MicroPine phase 3 trial for myopia to begin in 2019

The MicroPine program for the treatment of progressive myopia will begin a phase 3 pivotal study in 2019, according to a press release from Eyenovia.Eyenovia has received feedback that it will need to...

Eyenovia prices $27.3M IPO

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

Eyenovia MiDD Usability Study

This study is to evaluate the usability and patient tolerability for microtherapeutic dosing of commercially available ocular medication via the Eyenovia microdose delivery system (MiDD)

Companies [2 Associated Companies listed on BioPortfolio]

Eyenovia Inc.

Eyenovia is a specialty biopharmaceutical company building a portfolio of next generation topical eye treatments based on its proprietary delivery and formulation platform for mic...

Eyenovia, Inc.

More Information about "Eyenovia Inc." on BioPortfolio

We have published hundreds of Eyenovia Inc. news stories on BioPortfolio along with dozens of Eyenovia Inc. Clinical Trials and PubMed Articles about Eyenovia Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Eyenovia Inc. Companies in our database. You can also find out about relevant Eyenovia Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...


Corporate Database Quicklinks



Searches Linking to this Company Record